

## Maxacalcitol-D6

## Chemical Properties


CAS No. :

Formula: C<sub>26</sub>H<sub>36</sub>D<sub>6</sub>O<sub>4</sub>

Molecular Weight: 424.65

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Actual storage temperature shall be subject to the COA.



## Biological Description

Description	Maxacalcitol-D6 is a non-calcemic vitamin D3 analog and VDR ligand of VDR-like receptors. Maxacalcitol-D6 is the deuterated form of Maxacalcitol (T16015) (22-Oxacalcitriol).
In vitro	Maxacalcitol (22-Oxacalcitriol) suppresses parathyroid hormone (PTH) mRNA expression in vitro and in vivo. Maxacalcitol exhibits similar effects to calcitriol in osteoblast-like cells. Maxacalcitol (22-Oxacalcitriol) inhibits tumor growth of osteosarcoma in vitro in combination with all-trans retinoic acid.

## Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.3549 mL	11.7744 mL	23.5488 mL
5 mM	0.471 mL	2.3549 mL	4.7098 mL
10 mM	0.2355 mL	1.1774 mL	2.3549 mL
50 mM	0.0471 mL	0.2355 mL	0.471 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

## Reference

Monier-Faugere et al 22-Oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure. *Kidney Int.* (1999)55 821.

Barroga et al Inhibitory effects of 22-oxa-calcitriol and all-trans retinoic acid on the growth of a canine osteosarcoma derived cell-line in vivo and its pulmonary metastasis in vivo. *Res.Vet.Sci.* (2000)68 79.

Inoue K, Matsui I, Hamano T, Fujii N, Shimomura A, Nakano C, Kusunoki Y, Takabatake Y, Hirata M, Nishiyama A, Tsubakihara Y, Isaka Y, Rakugi H. Maxacalcitol ameliorates tubulointerstitial fibrosis in obstructed kidneys by recruiting PPM1A/VDR complex to pS

Karashima T, Hashikawa K, Ono F, Eguchi H, Hamada T, Ishii N, Dainichi T, Yasumoto S, Tsuruta D, Hashimoto T. Successful Treatment of Bowen's Disease with Topical Maxacalcitol. *Acta Derm Venereol.* 2012 Jan 26.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481